15 completed, 6 terminated, 2 active not recruiting, 2 recruiting. 27 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Completed 15, Terminated 6, Active not recruiting 2, Recruiting 2, Unknown 2 |
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Terminated 1 |
Follow Metastases: new trials by email Literature Review of Metastases trials Research Report on Metastases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases. LATTICE Radiotherapy, Standard radiotherapy - Metastases, Metastatic Cancer | Phase 2 | Recruiting | Stanford University | 80 | 2026-08-28 | 2026-09-09 |
| Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients Zanidatamab, Pembrolizumab, mFOLFOX - Gastroesophageal Adenocarcinoma, First Line Therapy | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 80 | 2026-01-16 | 2026-06-30 |
| Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC Sacituzumab tirumotecan, Anlotinib - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV | Phase 2 | Active not recruiting | Nanfang Hospital, Southern Medical University | 38 | 2025-08-13 | 2026-07-14 |
| Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC) Sintilimab, SBRT, Platinum based chemotherapy - Head and Neck Squamous Cell Carcinoma, Metastases | Phase 2 | Unknown | Jun-Lin Yi, MD | 50 | 2021-12-01 | 2021-11-29 |
| Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER) Buparlisib - Malignant Melanoma, Metastases | Phase 2 | Unknown | University Hospital Tuebingen | 22 | 2015-07-01 | 2017-05-03 |
| Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin iCasp9M28z T cell infusions, cyclophosphamide, pembrolizumab - Malignant Pleural Disease, Mesothelioma | Phase 1 / Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 113 | 2015-05-01 | 2026-07-22 |
| Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer Capecitabine, Bevacizumab, Radiotherapy - Colorectal Cancer, Metastases | Phase 2 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 1 | 2013-05-01 | 2022-07-01 |
| Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors. CELYVIR - Children, Solid Tumors | Phase 1 / Phase 2 | Completed | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | 20 | 2013-01-01 | 2016-02-19 |
| Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors Everolimus, embolization, Doxorubicin - Neuroendocrine Tumors, Hepatic Metastases | Phase 2 | Completed | Federation Francophone de Cancerologie Digestive | 74 | 2012-12-01 | 2024-09-25 |
| A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma AMG 386, AMG 386 Placebo, FOLFIRI - Cancer, Carcinoma | Phase 2 | Completed | Amgen | 144 | 2008-11-01 | 2015-09-02 |
| PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Panitumumab - Cancer, Carcinoma | Phase 2 | Completed | Amgen | 52 | 2007-10-30 | 2022-10-05 |
| Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement Cetuximab, Bevacizumab, Leucovorin - Colorectal Cancer, Metastases | Phase 2 | Terminated | Washington University School of Medicine | 9 | 2007-06-01 | 2016-12-20 |
| Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastases Ad.hIFN-β (BG00001, IDEC-201) - Colorectal Carcinoma, Metastases | Phase 1 / Phase 2 | Completed | Biogen | 44 | 2005-05-01 | 2009-07-14 |
| Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer Irinotecan - Colorectal Neoplasms, Metastases | Phase 2 | Terminated | Gachon University Gil Medical Center | 72 | 2005-04-01 | 2008-11-25 |
| Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer zoledronic acid - Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung | Phase 2 | Terminated | University of Louisville | 28 | 2005-02-01 | 2018-03-05 |
| Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma Unconjugated IDEC-159, 111In-IDEC-159, 90Y-IDEC-159 - Colorectal Cancer, Metastases | Phase 1 / Phase 2 | Terminated | Biogen | 30 | 2005-01-01 | 2010-08-27 |
| Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) Volociximab (anti-α5β1 integrin monoclonal antibody) - Renal Cell Carcinoma, Metastases | Phase 2 | Terminated | Abbott | 48 | 2005-01-01 | 2012-04-27 |
| Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy M200 (volociximab) in Combination with Dacarbazine (DTIC) - Melanoma, Metastases | Phase 2 | Completed | PDL BioPharma, Inc. | 40 | 2004-12-01 | 2008-08-05 |
| Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy cetuximab - Colorectal Neoplasms, Metastases | Phase 2 | Completed | Eli Lilly and Company | 87 | 2004-10-01 | 2011-05-25 |
| Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) ridaforolimus - Leiomyosarcoma, Liposarcoma | Phase 2 | Completed | Merck Sharp & Dohme LLC | 216 | 2004-10-01 | 2015-02-13 |
Showing 20 of 27. Sign in to see all of them.
Neoplasm Metastasis (27) · Colorectal Neoplasms (8) · Neoplasms (6) · Breast Neoplasms (4) · Carcinoma (3) · Melanoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Colonic Neoplasms (2) · Lung Neoplasms (2) · Carcinoma, Squamous Cell (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Leiomyosarcoma (1) · Liposarcoma (1)
Neoplastic Processes (27) · Pathologic Processes (27) · Pathological Conditions, Signs and Symptoms (27) · Neoplasms by Site (23) · Neoplasms (21) · Neoplasms by Histologic Type (11) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Gastrointestinal Diseases (9) · Colonic Diseases (8) · Gastrointestinal Neoplasms (8) · Intestinal Diseases (8) · Intestinal Neoplasms (8) · Rectal Diseases (8) · Skin Diseases (7)
Bevacizumab (3) · Cetuximab (2) · Panitumumab (2) · pembrolizumab (2) · volociximab (2) · Albumin-Bound Paclitaxel (1) · Capecitabine (1) · Chemoembolization, Therapeutic (1) · Cyclophosphamide (1) · Dacarbazine (1) · Denosumab (1) · Depsipeptides (1) · Diphosphonates (1) · Doxorubicin (1) · Drug Therapy (1)
Amgen (4) · Biogen (2) · Celgene (2) · Abbott (1) · Eisai Inc. (1) · Eli Lilly and Company (1) · Federation Francophone de Cancerologie Digestive (1) · Gachon University Gil Medical Center (1) · Genentech, Inc. (1) · Hospital Infantil Universitario Niño Jesús, Madrid, Spain (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Jun-Lin Yi, MD (1) · Memorial Sloan Kettering Cancer Center (1) · Merck Sharp & Dohme LLC (1) · Nanfang Hospital, Southern Medical University (1)
United States (13) · Germany (4) · Canada (3) · China (2) · France (2) · Argentina (1) · Mexico (1) · Netherlands (1) · Norway (1) · South Africa (1) · South Korea (1) · Spain (1) · Sweden (1)
Andres Forero, M.D. (2) · Agop Y. Bedikian, MD (1) · Alexander Stein, Prof. Dr. (1) · Antoni Ribas, MD (1) · Colin P. Curran, M.D. (1) · Cordula Petersen, Prof. (1) · David Linehan, M.D. (1) · Goetz H Kloecker, MD, MSPH (1) · John Kirkwood, M.D. (1) · Junlin Yi, MD (1) · Lee Cranmer, M.D. (1)
PMID 17876014, PMID 22067397, PMID 23361051, PMID 31678771, PMID 32053771, PMID 33737338, PMID 34213592, PMID 35045358, PMID 37146227, PMID 38321811
2004 (1), 2025 (1)